Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.
Takahashi H, Tada Y, Saotome T, Akazawa K, Ojiri H, Fushimi C, Masubuchi T, Matsuki T, Tani K, Osamura RY, Hirai H, Yamada S, Kawakita D, Miura K, Kamata SE, Nagao T. Takahashi H, et al. Among authors: saotome t. J Clin Oncol. 2019 Jan 10;37(2):125-134. doi: 10.1200/JCO.18.00545. Epub 2018 Nov 19. J Clin Oncol. 2019. PMID: 30452336 Clinical Trial.
A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma.
Fushimi C, Tada Y, Takahashi H, Nagao T, Ojiri H, Masubuchi T, Matsuki T, Miura K, Kawakita D, Hirai H, Hoshino E, Kamata S, Saotome T. Fushimi C, et al. Among authors: saotome t. Ann Oncol. 2018 Apr 1;29(4):979-984. doi: 10.1093/annonc/mdx771. Ann Oncol. 2018. PMID: 29211833 Free PMC article. Clinical Trial.
Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma.
Niwa K, Kawakita D, Nagao T, Takahashi H, Saotome T, Okazaki M, Yamazaki K, Okamoto I, Hirai H, Saigusa N, Fushimi C, Masubuchi T, Miura K, Okazaki SI, Matsui H, Okada T, Iwaki S, Matsuki T, Hanyu K, Tsukahara K, Oridate N, Tada Y. Niwa K, et al. Among authors: saotome t. Sci Rep. 2020 Oct 12;10(1):16988. doi: 10.1038/s41598-020-73965-6. Sci Rep. 2020. PMID: 33046752 Free PMC article.
Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade.
Lassche G, Tada Y, van Herpen CML, Jonker MA, Nagao T, Saotome T, Hirai H, Saigusa N, Takahashi H, Ojiri H, van Engen-Van Grunsven ACH, Schalken JA, Fushimi C, Verhaegh GW. Lassche G, et al. Among authors: saotome t. Cancers (Basel). 2021 Jul 14;13(14):3527. doi: 10.3390/cancers13143527. Cancers (Basel). 2021. PMID: 34298742 Free PMC article.
Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.
Kawakita D, Nagao T, Takahashi H, Kano S, Honma Y, Hirai H, Saigusa N, Akazawa K, Tani K, Ojiri H, Tsukahara K, Ozawa H, Okami K, Kondo T, Togashi T, Fushimi C, Shimura T, Shimizu A, Okamoto I, Okada T, Imanishi Y, Watanabe Y, Otsuka K, Sakai A, Ebisumoto K, Sato Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Ando M, Matsuki T, Nakaguro M, Sato Y, Urano M, Utsumi Y, Kohsaka S, Saotome T, Tada Y. Kawakita D, et al. Among authors: saotome t. Ther Adv Med Oncol. 2022 Sep 6;14:17588359221119538. doi: 10.1177/17588359221119538. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36090801 Free PMC article.
Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy.
Kodaira M, Takahashi S, Yamada S, Ueda K, Mishima Y, Takeuchi K, Yamamoto N, Ishikawa Y, Yokoyama M, Saotome T, Terui Y, Hatake K. Kodaira M, et al. Among authors: saotome t. Ann Oncol. 2010 Jun;21(6):1163-1167. doi: 10.1093/annonc/mdp583. Epub 2009 Dec 17. Ann Oncol. 2010. PMID: 20019088 Free article.
100 results